MX2022011671A - Vacunas contra el coronavirus y metodos de uso. - Google Patents
Vacunas contra el coronavirus y metodos de uso.Info
- Publication number
- MX2022011671A MX2022011671A MX2022011671A MX2022011671A MX2022011671A MX 2022011671 A MX2022011671 A MX 2022011671A MX 2022011671 A MX2022011671 A MX 2022011671A MX 2022011671 A MX2022011671 A MX 2022011671A MX 2022011671 A MX2022011671 A MX 2022011671A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- coronavirus vaccines
- coronavirus
- vaccines
- prevention
- Prior art date
Links
- 241000004176 Alphacoronavirus Species 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 241000711573 Coronaviridae Species 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6056—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Composiciones y métodos para la prevención y/o el tratamiento de una infección viral, en particular de la familia Coronaviridae.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062992666P | 2020-03-20 | 2020-03-20 | |
US202063026559P | 2020-05-18 | 2020-05-18 | |
US202063059582P | 2020-07-31 | 2020-07-31 | |
US202063086519P | 2020-10-01 | 2020-10-01 | |
US202063122904P | 2020-12-08 | 2020-12-08 | |
PCT/US2021/023267 WO2021188969A2 (en) | 2020-03-20 | 2021-03-19 | Coronavirus vaccines and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022011671A true MX2022011671A (es) | 2023-01-24 |
Family
ID=77771752
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022011671A MX2022011671A (es) | 2020-03-20 | 2021-03-19 | Vacunas contra el coronavirus y metodos de uso. |
Country Status (11)
Country | Link |
---|---|
US (2) | US20230141371A1 (es) |
EP (1) | EP4121104A2 (es) |
JP (1) | JP2023518821A (es) |
KR (1) | KR20230004508A (es) |
AU (1) | AU2021237720A1 (es) |
BR (1) | BR112022018819A2 (es) |
CA (1) | CA3172315A1 (es) |
IL (1) | IL296617A (es) |
MX (1) | MX2022011671A (es) |
TW (1) | TW202200199A (es) |
WO (1) | WO2021188969A2 (es) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3901261A1 (en) | 2020-04-22 | 2021-10-27 | BioNTech RNA Pharmaceuticals GmbH | Coronavirus vaccine |
TW202206098A (zh) * | 2020-08-11 | 2022-02-16 | 美商碩騰服務公司 | 抗冠狀病毒疫苗 |
CN112029781B (zh) * | 2020-08-14 | 2023-01-03 | 中山大学 | 一种新型冠状病毒SARS-CoV-2的安全型复制子系统及其应用 |
US20220088180A1 (en) * | 2020-08-31 | 2022-03-24 | The Broad Institute, Inc. | Immunogenic compositions and use thereof |
JP2022116482A (ja) * | 2021-01-29 | 2022-08-10 | 東亞合成株式会社 | SARS-CoV-2由来のアミノ酸配列およびその利用 |
CA3211678A1 (en) * | 2021-02-24 | 2022-09-01 | Biotome Pty Ltd | Peptides and their use in diagnosis of sars-cov-2 infection |
US20220356212A1 (en) * | 2021-03-26 | 2022-11-10 | Nanogen Pharmaceutical Biotechnology JSC | Modified spike protein and method of treatment |
EP4070814A1 (en) * | 2021-04-07 | 2022-10-12 | Lama France | Sars-cov-2 polypeptides and uses thereof |
EP4319803A1 (en) | 2021-04-08 | 2024-02-14 | Vaxthera SAS | Coronavirus vaccine comprising a mosaic protein |
WO2022268916A2 (en) * | 2021-06-23 | 2022-12-29 | Ose Immunotherapeutics | Pan-coronavirus peptide vaccine |
WO2023044542A1 (en) * | 2021-09-24 | 2023-03-30 | The University Of Adelaide | Sars cov-2 vaccine |
WO2023049983A1 (en) * | 2021-09-28 | 2023-04-06 | Medicago Inc. | Cpmv vlps displaying sars-cov-2 epitopes |
CN113981140B (zh) * | 2021-10-09 | 2024-02-27 | 广州达安基因股份有限公司 | 新型冠状病毒德尔塔突变株的检测方法及核酸检测试剂盒 |
AU2021470029A1 (en) * | 2021-10-21 | 2024-05-02 | BioNTech SE | Coronavirus vaccine |
WO2023067193A2 (en) | 2021-10-22 | 2023-04-27 | BioNTech SE | Compositions for administration of different doses of rna |
CA3235867A1 (en) | 2021-10-22 | 2023-04-27 | Munir MOSAHEB | Mrna vaccine composition |
CA3238764A1 (en) | 2021-11-23 | 2023-06-01 | Siddharth Patel | A bacteria-derived lipid composition and use thereof |
US20230203604A1 (en) * | 2021-11-23 | 2023-06-29 | nference, inc. | Detection of covid-19 associated cardiac injury and vaccine-associated myocarditis |
WO2023104154A1 (zh) * | 2021-12-08 | 2023-06-15 | 安达生物药物开发(深圳)有限公司 | 抗原性多肽及其用途 |
AU2022421841A1 (en) | 2021-12-20 | 2024-06-27 | Sail Biomedicines, Inc. | Mrna therapeutic compositions |
CN114686620B (zh) * | 2022-01-21 | 2024-05-07 | 生物岛实验室 | 新型冠状病毒多种变异株核酸质谱检测的引物组合、试剂盒及检测方法 |
EP4242308A1 (en) | 2022-01-27 | 2023-09-13 | Shenzhen Rhegen Biotechnology Co., Ltd. | Sars-cov-2 mrna vaccine, and preparation method therefor and use thereof |
WO2023147091A1 (en) * | 2022-01-28 | 2023-08-03 | BioNTech SE | Coronavirus vaccine |
WO2023144779A1 (en) * | 2022-01-28 | 2023-08-03 | Pfizer Inc. | Coronavirus antigen variants |
WO2023154734A2 (en) * | 2022-02-08 | 2023-08-17 | Iowa State University Research Foundation, Inc. | Mrna expression and delivery systems |
GB202201768D0 (en) * | 2022-02-11 | 2022-03-30 | Virax Biolabs Uk Ltd | Peptides |
WO2023166061A1 (en) * | 2022-03-02 | 2023-09-07 | ISR Immune System Regulation Holding AB (publ) | Vaccine composition comprising an antigen and a tlr3 agonist |
CN116768988A (zh) * | 2022-03-09 | 2023-09-19 | 中生复诺健生物科技(上海)有限公司 | 编码新型冠状病毒S蛋白的mRNA疫苗 |
CN114907453B (zh) * | 2022-04-08 | 2023-07-25 | 国科宁波生命与健康产业研究院 | 一种用于治疗SARS-CoV-2病毒感染的S蛋白多肽 |
CN114907452B (zh) * | 2022-04-08 | 2023-07-25 | 国科宁波生命与健康产业研究院 | 一种用于治疗SARS-CoV-2病毒感染的M蛋白多肽 |
CN114907454A (zh) * | 2022-04-08 | 2022-08-16 | 国科宁波生命与健康产业研究院 | 一种用于治疗SARS-CoV-2病毒感染的N蛋白多肽 |
TW202406929A (zh) | 2022-05-05 | 2024-02-16 | 比利時商eTheRNA免疫治療公司 | 多表位構築體 |
WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
WO2024123139A1 (ko) * | 2022-12-09 | 2024-06-13 | 주식회사 나이벡 | 타겟 세포 내로 올리고뉴클레오티드를 전달하기 위한 펩타이드 기반 결합체를 포함하는 나노입자 및 이를 포함하는 약학적 조성물 |
WO2024123134A1 (ko) * | 2022-12-09 | 2024-06-13 | 서울대학교산학협력단 | B 세포 및 t 세포 내로 mrna를 전달하기 위한 펩타이드 기반 결합체를 포함하는 나노입자 및 이의 용도 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005012337A2 (en) * | 2003-07-15 | 2005-02-10 | Crucell Holland B.V. | Antigenic peptides of sars coronavirus and uses thereof |
NO2788478T3 (es) * | 2011-12-09 | 2018-01-20 | ||
WO2017013170A1 (en) * | 2015-07-22 | 2017-01-26 | F. Hoffmann-La Roche Ag | Identification of antigen epitopes and immune sequences recognizing the antigens |
-
2021
- 2021-03-19 WO PCT/US2021/023267 patent/WO2021188969A2/en active Application Filing
- 2021-03-19 CA CA3172315A patent/CA3172315A1/en active Pending
- 2021-03-19 BR BR112022018819A patent/BR112022018819A2/pt unknown
- 2021-03-19 MX MX2022011671A patent/MX2022011671A/es unknown
- 2021-03-19 KR KR1020227036217A patent/KR20230004508A/ko active Search and Examination
- 2021-03-19 JP JP2022557136A patent/JP2023518821A/ja active Pending
- 2021-03-19 IL IL296617A patent/IL296617A/en unknown
- 2021-03-19 AU AU2021237720A patent/AU2021237720A1/en active Pending
- 2021-03-19 TW TW110110089A patent/TW202200199A/zh unknown
- 2021-03-19 EP EP21772515.9A patent/EP4121104A2/en active Pending
- 2021-03-19 US US17/912,841 patent/US20230141371A1/en active Pending
- 2021-09-22 US US17/481,781 patent/US20230083931A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4121104A2 (en) | 2023-01-25 |
TW202200199A (zh) | 2022-01-01 |
JP2023518821A (ja) | 2023-05-08 |
US20230141371A1 (en) | 2023-05-11 |
CA3172315A1 (en) | 2021-09-23 |
WO2021188969A3 (en) | 2021-11-25 |
US20230083931A1 (en) | 2023-03-16 |
AU2021237720A1 (en) | 2022-11-17 |
KR20230004508A (ko) | 2023-01-06 |
BR112022018819A2 (pt) | 2022-11-29 |
IL296617A (en) | 2022-11-01 |
WO2021188969A2 (en) | 2021-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022011671A (es) | Vacunas contra el coronavirus y metodos de uso. | |
WO2018115527A3 (en) | Mers coronavirus vaccine | |
IL168584A (en) | West nile virus vaccine | |
WO2022217155A3 (en) | Thionucleosides as antiviral agents | |
NO20064547L (no) | Fremgangsmater for behandling av HIV infeksjon | |
MX2018005230A (es) | Terapia de combinacion de un inhibidor del ensamble de la capside del hbv y un interferon. | |
WO2007002470A3 (en) | Inactivated chimeric vaccines and related methods of use | |
MX2021007602A (es) | Derivados de heteroarildihidropirimidina y metodos de tratamiento de infecciones de hepatitis b. | |
MX2022014034A (es) | Métodos para tratar covid-19 con el uso de bardoxolona metilo o análogos de esta. | |
MX2022014561A (es) | Inhibidores de mek para el tratamiento o prevencion de infecciones por coronavirus y/o tormenta de citocinas por covid-19. | |
MX2022002174A (es) | Composicion de te con eficacia para prevenir o mejorar enfermedades respiratorias, y composicion farmaceutica que comprende la misma. | |
PH12021551369A1 (en) | Substituted arylmethylureas and heteroarylmethylureas, analogues thereof, and methods using same | |
MX2018006416A (es) | Metodos para el tratamiento, prevencion y diagnostico de infeccion por el virus de la diarrea epidemica porcina. | |
MY153290A (en) | Multivalent avian influenza vaccines | |
MX2021015448A (es) | Células linfocíticas activadas y métodos para usarlas para tratar cáncer y afecciones infecciosas. | |
PH12017550047B1 (en) | Use of taurine in prevention and/or treatment of diseases induced by viruses of genus coronavirus and/or genus rotavirus | |
MX2022010920A (es) | Pld para uso en combinación con el tratamiento de coronavirus. | |
MX2022013195A (es) | Uso de proteina surfactante d para tratar infecciones virales. | |
PH12020551944A1 (en) | Reverse peptide vaccine | |
UA90477C2 (ru) | Способ лечения гепатита с (варианты) | |
MX2022012262A (es) | Fitoecdisonas y derivados de estas para su uso en el tratamiento de insuficiencia de la funcion respiratoria durante una infeccion viral. | |
EP4121038A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CORONAVIRUS INFECTION AND RESPIRATORY COMPROMISE | |
MX2020011738A (es) | Uso de calcifediol en pacientes de cirugia bariatrica. | |
MX2022004570A (es) | Vacunas contra el virus de la gripe y usos de estas. | |
GB0220257D0 (en) | Vaccine |